Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2). 1994

P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
Department of Immunology, Erasmus University, Rotterdam, The Netherlands.

IL-4 up-regulates various monocytic properties that are associated with pro-inflammatory functions. Paradoxically, IL-4 may also act as an anti-inflammatory agent by down-regulating the production of several inflammatory mediators. As the activity of some mediators has recently been shown to be regulated by peptidases, we examined whether IL-4 was able to modulate the expression of a cell membrane-associated peptidase, aminopeptidase-N (CD13). IL-4 caused a dose-dependent increase in the expression of CD13 Ag on highly purified human blood monocytes. Maximal expression was observed around 48 h of culture. This IL-4-induced increase was completely blocked by anti-IL-4 antiserum. Furthermore, the increase in surface expression was preceded by increased mRNA levels of CD13, which was maximal around 24 h of culture. We also observed that CD13-mediated leucine-aminopeptidase activity of monocytes was induced by IL-4. Other CD13-expressing cells were also sensitive to IL-4, as CD13 Ag expression and CD13 mRNA levels were up-regulated in human alveolar macrophages and endothelial cells upon IL-4 treatment. The increased expression of cell membrane aminopeptidase-N represents a potentially increased cellular ability to inactivate inflammatory mediators. Therefore, these findings represent further evidence of IL-4-mediated anti-inflammatory actions. We postulate that up-regulation of aminopeptidase-N expression may be an indirect mechanism of IL-4 to modulate the action of bioactive peptides. This mechanism may underlie, at least partially, the anti-inflammatory effects of IL-4 in vivo.

UI MeSH Term Description Entries
D007931 Leucyl Aminopeptidase A zinc containing enzyme of the hydrolase class that catalyzes the removal of the N-terminal amino acid from most L-peptides, particularly those with N-terminal leucine residues but not those with N-terminal lysine or arginine residues. This occurs in tissue cell cytosol, with high activity in the duodenum, liver, and kidney. The activity of this enzyme is commonly assayed using a leucine arylamide chromogenic substrate such as leucyl beta-naphthylamide. Cytosol Aminopeptidase,Leucine Aminopeptidase,L-Leucylnaphthylamidase,Methoxyleucine Aminopeptidase,Peptidase S,Zinc-Manganese-Leucine Aminopeptidase,Aminopeptidase, Cytosol,Aminopeptidase, Leucine,Aminopeptidase, Leucyl,Aminopeptidase, Methoxyleucine,Aminopeptidase, Zinc-Manganese-Leucine,Zinc Manganese Leucine Aminopeptidase
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000626 Aminopeptidases A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11. Aminopeptidase
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015152 Blotting, Northern Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES. Northern Blotting,Blot, Northern,Northern Blot,Blots, Northern,Blottings, Northern,Northern Blots,Northern Blottings
D015214 Antigens, Differentiation, Myelomonocytic Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas. Differentiation Antigens, Myelomonocytic,Myelomonocytic Differentiation Antigens,Antigens, Myelomonocytic, Differentiation,Antigens, Myelomonocytic Differentiation

Related Publications

P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
October 1997, Biochimica et biophysica acta,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
January 2006, Medicinal research reviews,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
April 2005, Life sciences,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
May 2008, International immunopharmacology,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
April 1997, Journal of immunology (Baltimore, Md. : 1950),
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
January 2011, Immunobiology,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
June 2005, Journal of leukocyte biology,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
June 1999, Bioorganic & medicinal chemistry letters,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
January 2013, BioMed research international,
P T van Hal, and J P Hopstaken-Broos, and A Prins, and E J Favaloro, and R J Huijbens, and C Hilvering, and C G Figdor, and H C Hoogsteden
January 2020, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!